ClinicalTrials.gg
Status unknownNCT00791700Updated Apr 28, 2020Results posted

An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children

A Phase 2 interventional study of Maraviroc in Human Immunodeficiency Virus, sponsored by ViiV Healthcare. Status unknown at 41 sites in 9 countries. Open to participants aged 2 Years to 18 Years. Per ClinicalTrials.gov, last updated 2020-04-28.

Primary conditionAcquired Immunodeficiency Syndrome(the registry's first term)UnverifiedIs this wrong?The registry often attaches Acquired Immunodeficiency Syndrome to studies about something else, and this study's title and listed conditions do not name it. No better condition is named, so the registry's term is kept.

Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Apr 2020), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
103
Ages
2 Years to 18 Years
Sex
All
01

Study summary

The primary purpose of this study is to determine the pharmacokinetic properties (what the body does to maraviroc) and to determine a suitable dosing schedule of maraviroc in HIV-1 infected children and adolescents. This study will also determine whether maraviroc is safe to use in children and adolescents.

02

Conditions studied

  • Human Immunodeficiency Virus

Browse trials for

Keywords

  • Open label pharmacokinetic safety and efficacy in HIV-1 infected pediatrics
03

In context

Acquired Immunodeficiency Syndrome Unverified

3,038 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 308 are open to participants now.

This study's enrollment of 103 is close to the median of 96 across 2,253 interventional studies indexed under Acquired Immunodeficiency Syndrome.

Browse Acquired Immunodeficiency Syndrome studies →

Lead sponsor

ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.

Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.

Compared within Acquired Immunodeficiency Syndrome, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →

04

Who can participate

Ages eligible
2 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who are 2-18 years of age, treatment experienced for 6 months or longer with at least 2 ARV drug classes, with -1 RNA ≥1,000 copies/mL

Exclusion criteria

Exclusion Criteria:

  • X4- or dual/mixed-tropic virus detected by the Trofile™ viral tropism assay
  • Concomitant therapy with other agents (other than experimental ARV agents available through pre-approval access programs)
  • Known ≥Grade 3 of any of the following laboratory tests at Screening or within 30 days prior to Baseline Visit: , , , , ALT, and creatinine, lipase;
  • Total ≥Grade 3, unless ALL of the following are true: Current regimen includes atazanavir; ALT/AST \< 2.5 X ; No symptoms other than jaundice or icterus.
  • Other laboratory values ≥Grade 3, must be reviewed by Pfizer.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
103 participants (actual)

Study arms

  • Experimental
    Maraviroc

    Subjects will be stratified by age and formulation into one of the following cohorts: Cohort 1: ≥2-\<6 years of age, maraviroc liquid formulation; Cohort 2: ≥6-\<12 years of age, maraviroc tablet formulation; Cohort 3: ≥6-\<12 years of age, maraviroc liquid formulation and Cohort 4: ≥12-\<18 years of age, maraviroc tablet formulation.

    Drug: Maraviroc

Interventions

  • Maraviroc will be administered twice daily either as a liquid or tablet formulation, depending on the age of the subject. The dosage administered will be dependent upon the subject's body surface area as well as the background therapy.

    Also known as: Selzentry

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic(PK): Maraviroc PK Parameter, Average Plasma Concentration (Cavg), Trough Concentration(Cmin), Maximum Plasma Concentration (Cmax)

    Cavg: calculated as area under the curve divided by a dosing interval of 12 hours. Cmin: directly observed plasma concentration prior to the next dose. Geometric Coefficient of Variation is defined as the geometric standard deviation to the power of the reciprocal of the geometric mean.

    Time frame: Week 2 and Week 48 (0, 1, 2, 4, 6, 8, 12 hours post-dose)

  2. Area Under the Curve at Steady State (AUCtau)

    AUCtau is the area under the plasma concentration time curve (AUC) at steady state from time zero (pre-dose) to end of dosing interval (tau), here dosing interval is 12 hours.

    Time frame: Week 2 and Week 48 (0, 1, 2, 4, 6, 8, 12 hours post-dose)

  3. Time to Reach Maximum Plasma Concentration (Tmax)

    Time frame: Week 2 and Week 48 (0, 1, 2, 4, 6, 8, 12 hours post-dose)

  4. Incidence and Severity of Grade 3 and Grade 4 Treatment-Emergent Adverse Events(AEs) (All Causality)

    Incidence is reported in terms of number of events of AEs. The investigator used the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric AEs as follows: Grade 1= Symptoms causing no or minimal interference with usual social and functional activities; Grade 2= Symptoms causing greater than minimal interference with usual social and functional activities; Grade 3= Symptoms causing inability to perform usual social and functional activities; Grade 4= Symptoms causing inability to perform basic self-care functions or medical or operative intervention indicated to prevent permanent impairment, persistent disability, or death. Data have been reported in the measure for Grade 3 and 4 as per system organ class and preferred term.

    Time frame: Baseline up to 5 years

  5. Treatment Discontinuation: Secondary Reasons- Serious Adverse Event (SAE) Related to Study Drug

    The primary reason for a participant discontinuing from study drug or the clinical study was recorded in the source documents as well as the case report form. A discontinuation had to be reported immediately to the study medical monitor or his/her designated representative if it was due to an SAE and was considered as a secondary reason.

    Time frame: Baseline up to 5 years

Secondary outcomes

  1. Percentage of Participants With HIV-1 RNA <400 Copies/mL Through Week 48 Using Missing, Discontinuation = Failure (MD=F) Approach

    The proportion of participants who achieved HIV-1 RNA \<400 copies/mL at week 24 or 48 was assessed according to Food and Drug Administration's (FDA's) Missing, Switch, Discontinuation'=Failure (MSDF) Snapshot algorithm. The algorithm uses the plasma HIV-1 RNA in the Week 24 or 48 visit window, follows the "virology-first principle" and considers a participant who has a missing plasma HIV-1 RNA, or switches to prohibited ARV regimen or discontinues from the study or study drug for any reason, or dies, as a failure.

    Time frame: Week 24 and Week 48 post-treatment

  2. Percentage of Participants With HIV-1 RNA <48 Copies/mL Through Week 48 Using Missing, Discontinuation = Failure (MD=F)Approach

    The proportion of participants who achieved HIV-1 RNA \<48 copies/mL at week 24 or 48 was assessed according to Food and Drug Administration's (FDA's) Missing, Switch, Discontinuation'=Failure (MSDF) Snapshot algorithm. The algorithm uses the plasma HIV-1 RNA in the Week 24 or 48 visit window, follows the "virology-first principle" and considers a participant who has a missing plasma HIV-1 RNA, or switches to prohibited ARV regimen or discontinues from the study or study drug for any reason, or dies, as a failure.

    Time frame: Week 24 and Week 48 post-treatment

  3. Percentage of Participants With HIV-1 RNA Levels <400 Copies/mL at Weeks 24 and 48 Using Missing, Discontinuation = Failure (MD=F)Approach

    Participants who have been discontinued from the study, have been lost to follow-up, or have missing HIV-1 RNA data prior to the time point of interest were considered to have HIV-1 RNA levels \> lower limit of quantification (LLOQ) . This referred to as \[non-completer = failure; NC=F\] or \[missing, discontinuation = failure; MD=F\].

    Time frame: Week 24 and Week 48 post-treatment

  4. Percentage of Participants With HIV-1 RNA Levels < 48 Copies/mL at Weeks 24 and 48 Using MD=F Approach

    Participants who have been discontinued from the study, have been lost to follow-up, or have missing HIV-1 RNA data prior to the time point of interest were considered to have HIV-1 RNA levels \> lower limit of quantification (LLOQ) . This referred as \[non-completer = failure; NC=F\] or \[missing, discontinuation = failure; MD=F\].

    Time frame: Week 24 and Week 48 post-treatment

  5. Percentage of Participants With HIV-1 RNA <400 Copies/mL and <48 Copies/mL Using the Time to Loss of Virologic Response Algorithm (TLOVR) at Week 48

    TLOVR is defined as the time from first dose of study medication (Day 1) until the time of virologic failure using the a TLOVR algorithm.

    Time frame: Week 48

  6. Percentage of Participants With >= 1.0 log10 Reduction in HIV-1RNA Concentration From Baseline to Week 24 and Week 48

    Percentage of participants with at least a 1.0 log10 reduction in HIV-1 RNA from baseline to Week 24 and Week 48 were tabulated.

    Time frame: Baseline to Week 24, Week 48 post-treatment

  7. Change From Baseline in HIV-1 RNA (Original)

    Plasma HIV-1 RNA was determined using the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 Test (lower limit of quantification \[LLOQ\] \<48 copies/mL). Blood samples were taken at the time points indicated in the participant evaluation schedule. Screening HIV-1 RNA \>1000 copies/ml was used to determine eligibility for the study.

    Time frame: Baseline, Week 24, Week 48 post-treatment

  8. Change From Baseline in HIV-1 RNA (Log10 Copies/mL)

    Plasma HIV-1 RNA was determined using the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 Test (lower limit of quantification \[LLOQ\] \<48 copies/mL). Blood samples were taken at the time points indicated in the participant evaluation schedule. Screening HIV-1 RNA \>1000 copies/ml was used to determine eligibility for the study.

    Time frame: Baseline, Week 24, Week 48 post-treatment

  9. Change From Baseline in Cluster of Differentiation 4 (CD4+) Cell Count at Weeks 24 and 48

    Change from baseline in CD4 cell count to Week 24 and Week 48 were tabulated in aggregated and broken down by age cohort using summary statistics.

    Time frame: Baseline, Week 24, Week 48 post-treatment

  10. Change From Baseline in Percentage (%) of CD4+ Cells at Weeks 24 and 48

    Change from baseline in CD4 % to Week 24 and Week 48 were tabulated in aggregated and broken down by age cohort using summary statistics.

    Time frame: Baseline, Week 24 and Week 48 post-treatment

  11. Number of Participants With Protocol Defined Virologic Failure

    The occurrence of any one of the following criteria would constitute Virologic failure: Criteria A=Decrease from Baseline plasma HIV-1 RNA \<1 log10 and plasma HIV-1 RNA \>400 copies/mL starting at Week 12 and confirmed at consecutive Week 16; Criteria B=Decrease from Baseline plasma HIV-1 RNA \<2.0 log10 and plasma HIV-1 RNA \>400 copies/mL at Week 24 OR plasma HIV-1 RNA \>10,000 copies/mL on and after Week 24, and confirmed within 14 to 21 days; Criteria C=Increase from nadir plasma HIV-1 RNA of \>=1 log10 (\>=1,000 copies/mL if nadir plasma HIV-1 RNA \<48 copies/mL) at any time, and confirmed within 14 to 21 days.

    Time frame: Week 48

  12. Number of Participants With Viral Tropism Between Screening and Confirmed Protocol Defined Virologic Failure (PDVF) Prior to Week 48

    Virus tropism was determined using the Monogram Biosciences Trofile™ viral tropism assay. Change in detected tropism from screening to the time of failure prior to Week 48 was reported. X4=CXCR4 tropic virus; R5=CCR5-tropic virus; X4=CXCR4-tropic virus. Number of participants as per tropism to respective virus has been reported.

    Time frame: Screening to Week 48

  13. Number of Participants With Emergence of Reverse Transcriptase Inhibitor (RTI) and Protease Inhibitor (PI) Resistance Associated Mutations (RAMs) Between Screening and On-Treatment Confirmed PDVF

    Phenotypic and genotypic susceptibility to reverse transcriptase and protease inhibitors was evaluated at screening using the Monogram Biosciences PhenoSense™ GT (PSGT) assay. Samples from a confirmatory PDVF visit or early termination of MVC were planned to be analyzed if the plasma HIV-1 RNA was ≥400 copies/mL. Data for participants with respective gene mutation category has been reported. Participants with more than one mutation are counted more than once.

    Time frame: 48 weeks

  14. Percentage of Participants With Optimized Background Treatment Susceptibility Scores

    Data was summarized by the total ARV activity of the background regimen using simple and weighted total optimized background treatment susceptibility scores as well as by screening genotype. Simple total optimized background treatment (OBT) susceptibility scores were categorized as 0, 1, \>=2 and weighted total OBT susceptibility scores were categorized as 0 to 0.5, 1 to 1.5 and \>=2. However, net susceptibility scores were imputed for simple analysis based on genotype. Susceptibility scores indicate the level resistance to the study medication. Scores ranged from 0 to 1 as 1 = susceptible and potential low-level resistance; 0.5 = low and intermediate-level resistance; 0 = high-level resistance, where higher scores indicated lower resistance.

    Time frame: 48 weeks

07

Results

Posted Feb 25, 2016

Participant flow

This open-label, multicenter, multiple dose pharmacokinetic, safety and efficacy study at 24 sites in 8 countries.

Participant flow — Overall Study
Milestone>=2 - <6 Years of Age, MVC Liquid Formulation>=6 - <12 Years of Age, MVC Tablet Formulation>=6 - <12 Years of Age, MVC Liquid Formulation>=12 - <18 Years of Age, MVC Tablet Formulation
Started16311343
Completed1020713
Not completed611630
Withdrew: Insufficient clinical response1418
Withdrew: No longer willing to participate1108
Withdrew: Non-compliance with study treatment0204
Withdrew: Withdrawn due to pregnancy0001
Withdrew: Other0101
Withdrew: Death0001
Withdrew: Lost to follow-up4346
Withdrew: Adverse event0011

Outcome measures

PrimaryPharmacokinetic(PK): Maraviroc PK Parameter, Average Plasma Concentration (Cavg), Trough Concentration(Cmin), Maximum Plasma Concentration (Cmax)

Cavg: calculated as area under the curve divided by a dosing interval of 12 hours. Cmin: directly observed plasma concentration prior to the next dose. Geometric Coefficient of Variation is defined as the geometric standard deviation to the power of the reciprocal of the geometric mean.

Time frame:
Week 2 and Week 48 (0, 1, 2, 4, 6, 8, 12 hours post-dose)
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
Pharmacokinetic(PK): Maraviroc PK Parameter, Average Plasma Concentration (Cavg), Trough Concentration(Cmin), Maximum Plasma Concentration (Cmax)
nanogram per milliliter (ng/mL)>=2 - <6 Years of Age, MVC Liquid Formulation>=6 - <12 Years of Age, MVC Tablet Formulation>=6 - <12 Years of Age, MVC Liquid Formulation>=12 - <18 Years of Age, MVC Tablet Formulation
Cavg-Week2237.34 ± 63260.65 ± 43264.45 ± 62239.85 ± 67
Cavg-Week 48163.73 ± 146289.69 ± 50168.62 ± 117199.12 ± 78
Cmax-Week2581.47 ± 69546.80 ± 51444.37 ± 61530.80 ± 62
Cmax-Week 48334.68 ± 156593.68 ± 25284.96 ± 128423.32 ± 48
Cmin-Week218.97 ± 202208100.02 ± 39115.84 ± 9056.17 ± 145
Cmin-Week 4848.11 ± 18082.21 ± 12060.03 ± 24566.51 ± 140
PrimaryArea Under the Curve at Steady State (AUCtau)

AUCtau is the area under the plasma concentration time curve (AUC) at steady state from time zero (pre-dose) to end of dosing interval (tau), here dosing interval is 12 hours.

Time frame:
Week 2 and Week 48 (0, 1, 2, 4, 6, 8, 12 hours post-dose)
Reported as:
Geometric mean · ng*hr/mL
Area Under the Curve at Steady State (AUCtau)
ng*hr/mL>=2 - <6 Years of Age, MVC Liquid Formulation>=6 - <12 Years of Age, MVC Tablet Formulation>=6 - <12 Years of Age, MVC Liquid Formulation>=12 - <18 Years of Age, MVC Tablet Formulation
AUCtau - Week 22848.1 ± 633127.7 ± 433173.4 ± 622878.2 ± 67
AUCtau - Week 481964.7 ± 1463476.3 ± 502023.5 ± 1172389.4 ± 78
PrimaryTime to Reach Maximum Plasma Concentration (Tmax)
Time frame:
Week 2 and Week 48 (0, 1, 2, 4, 6, 8, 12 hours post-dose)
Reported as:
Median · hour
Time to Reach Maximum Plasma Concentration (Tmax)
hour>=2 - <6 Years of Age, MVC Liquid Formulation>=6 - <12 Years of Age, MVC Tablet Formulation>=6 - <12 Years of Age, MVC Liquid Formulation>=12 - <18 Years of Age, MVC Tablet Formulation
Tmax - Week 22.000 (0.97 to 6.00)4.000 (0.75 to 6.00)2.000 (1.00 to 4.00)2.000 (1.00 to 4.00)
Tmax - Week 482.000 (0.00 to 6.03)2.000 (1.00 to 8.00)3.000 (0.00 to 6.00)2.000 (1.00 to 4.00)
PrimaryIncidence and Severity of Grade 3 and Grade 4 Treatment-Emergent Adverse Events(AEs) (All Causality)

Incidence is reported in terms of number of events of AEs. The investigator used the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric AEs as follows: Grade 1= Symptoms causing no or minimal interference with usual social and functional activities; Grade 2= Symptoms causing greater than minimal interference with usual social and functional activities; Grade 3= Symptoms causing inability to perform usual social and functional activities; Grade 4= Symptoms causing inability to perform basic self-care functions or medical or operative intervention indicated to prevent permanent impairment, persistent disability, or death. Data have been reported in the measure for Grade 3 and 4 as per system organ class and preferred term.

Time frame:
Baseline up to 5 years
Reported as:
Number · events
Incidence and Severity of Grade 3 and Grade 4 Treatment-Emergent Adverse Events(AEs) (All Causality)
eventsCohort 1 (Grade 3)Cohort 1 (Grade 4)Cohort 2 (Grade 3)Cohort 2 (Grade 4)Cohort 3 (Grade 3)Cohort 3 (Grade 4)Cohort 4 (Grade 3)Cohort 4 (Grade 4)
Gastrointestinal disorders - Vomiting10100000
Hepat. disorders - Drug-induced liver injury00000001
Infections and infestations - H1N1 influenza00000010
Infections and infestations - Pneumonia00001010
Investigations - Lipase increased01000000
Pyschiatric disorder - Bipolar disorder00100000
Gastrointestinal disorders - Gastritis00100000
Investigations - Hepatic enzyme abnormal00100000
Investigations - Transaminases increased00100000
Pyschiatric disorder - Aggression00100000
Blood and lymphatic system disorders - Anaemia00000010
Infections and infestations - Meningitis00000001
Infections and infestations -Otitis media00100000
PrimaryTreatment Discontinuation: Secondary Reasons- Serious Adverse Event (SAE) Related to Study Drug

The primary reason for a participant discontinuing from study drug or the clinical study was recorded in the source documents as well as the case report form. A discontinuation had to be reported immediately to the study medical monitor or his/her designated representative if it was due to an SAE and was considered as a secondary reason.

Time frame:
Baseline up to 5 years
Reported as:
Number · participants
Treatment Discontinuation: Secondary Reasons- Serious Adverse Event (SAE) Related to Study Drug
participants>=2 - <6 Years of Age, MVC Liquid Formulation>=6 - <12 Years of Age, MVC Tablet Formulation>=6 - <12 Years of Age, MVC Liquid Formulation>=12 - <18 Years of Age, MVC Tablet Formulation
Treatment Discontinuation: Secondary Reasons- Serious Adverse Event (SAE) Related to Study Drug0000
SecondaryPercentage of Participants With HIV-1 RNA <400 Copies/mL Through Week 48 Using Missing, Discontinuation = Failure (MD=F) Approach

The proportion of participants who achieved HIV-1 RNA \<400 copies/mL at week 24 or 48 was assessed according to Food and Drug Administration's (FDA's) Missing, Switch, Discontinuation'=Failure (MSDF) Snapshot algorithm. The algorithm uses the plasma HIV-1 RNA in the Week 24 or 48 visit window, follows the "virology-first principle" and considers a participant who has a missing plasma HIV-1 RNA, or switches to prohibited ARV regimen or discontinues from the study or study drug for any reason, or dies, as a failure.

Time frame:
Week 24 and Week 48 post-treatment
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA <400 Copies/mL Through Week 48 Using Missing, Discontinuation = Failure (MD=F) Approach
percentage of participants>=2 - <6 Years of Age, MVC Liquid Formulation>=6 - <12 Years of Age, MVC Tablet Formulation>=6 - <12 Years of Age, MVC Liquid Formulation>=12 - <18 Years of Age, MVC Tablet Formulation
Week 2468.890.369.262.8
Week 4875.077.469.251.2
SecondaryPercentage of Participants With HIV-1 RNA <48 Copies/mL Through Week 48 Using Missing, Discontinuation = Failure (MD=F)Approach

The proportion of participants who achieved HIV-1 RNA \<48 copies/mL at week 24 or 48 was assessed according to Food and Drug Administration's (FDA's) Missing, Switch, Discontinuation'=Failure (MSDF) Snapshot algorithm. The algorithm uses the plasma HIV-1 RNA in the Week 24 or 48 visit window, follows the "virology-first principle" and considers a participant who has a missing plasma HIV-1 RNA, or switches to prohibited ARV regimen or discontinues from the study or study drug for any reason, or dies, as a failure.

Time frame:
Week 24 and Week 48 post-treatment
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA <48 Copies/mL Through Week 48 Using Missing, Discontinuation = Failure (MD=F)Approach
percentage of participants>=2 - <6 Years of Age, MVC Liquid Formulation>=6 - <12 Years of Age, MVC Tablet Formulation>=6 - <12 Years of Age, MVC Liquid Formulation>=12 - <18 Years of Age, MVC Tablet Formulation
Week 2418.7564.561.548.8
Week 4850.054.853.839.5
SecondaryPercentage of Participants With HIV-1 RNA Levels <400 Copies/mL at Weeks 24 and 48 Using Missing, Discontinuation = Failure (MD=F)Approach

Participants who have been discontinued from the study, have been lost to follow-up, or have missing HIV-1 RNA data prior to the time point of interest were considered to have HIV-1 RNA levels \> lower limit of quantification (LLOQ) . This referred to as \[non-completer = failure; NC=F\] or \[missing, discontinuation = failure; MD=F\].

Time frame:
Week 24 and Week 48 post-treatment
Reported as:
Number · Percentage of participants
Percentage of Participants With HIV-1 RNA Levels <400 Copies/mL at Weeks 24 and 48 Using Missing, Discontinuation = Failure (MD=F)Approach
Percentage of participants>=2 - <6 Years of Age, MVC Liquid Formulation>=6 - <12 Years of Age, MVC Tablet Formulation>=6 - <12 Years of Age, MVC Liquid Formulation>=12 - <18 Years of Age, MVC Tablet Formulation
Week 2462.5 (38.8 to 86.2)87.10 (75.3 to 98.9)69.2 (44.1 to 94.3)62.8 (48.3 to 77.2)
Week 4875.0 (53.8 to 96.2)74.2 (58.8 to 89.6)69.2 (44.1 to 94.3)51.2 (36.2 to 66.1)
SecondaryPercentage of Participants With HIV-1 RNA Levels < 48 Copies/mL at Weeks 24 and 48 Using MD=F Approach

Participants who have been discontinued from the study, have been lost to follow-up, or have missing HIV-1 RNA data prior to the time point of interest were considered to have HIV-1 RNA levels \> lower limit of quantification (LLOQ) . This referred as \[non-completer = failure; NC=F\] or \[missing, discontinuation = failure; MD=F\].

Time frame:
Week 24 and Week 48 post-treatment
Reported as:
Number · Percentage of participants
Percentage of Participants With HIV-1 RNA Levels < 48 Copies/mL at Weeks 24 and 48 Using MD=F Approach
Percentage of participants>=2 - <6 Years of Age, MVC Liquid Formulation>=6 - <12 Years of Age, MVC Tablet Formulation>=6 - <12 Years of Age, MVC Liquid Formulation>=12 - <18 Years of Age, MVC Tablet Formulation
Week 2418.8 (0.0 to 37.9)64.5 (47.7 to 81.4)61.5 (35.1 to 89.0)48.8 (33.9 to 63.8)
Week 4850.0 (25.5 to 74.5)54.8 (34.0 to 69.2)53.8 (35.1 to 89.0)39.5 (24.9 to 54.2)
SecondaryPercentage of Participants With HIV-1 RNA <400 Copies/mL and <48 Copies/mL Using the Time to Loss of Virologic Response Algorithm (TLOVR) at Week 48

TLOVR is defined as the time from first dose of study medication (Day 1) until the time of virologic failure using the a TLOVR algorithm.

Time frame:
Week 48
Reported as:
Number · Percentage of participants
Percentage of Participants With HIV-1 RNA <400 Copies/mL and <48 Copies/mL Using the Time to Loss of Virologic Response Algorithm (TLOVR) at Week 48
Percentage of participants>=2 - <6 Years of Age, MVC Liquid Formulation>=6 - <12 Years of Age, MVC Tablet Formulation>=6 - <12 Years of Age, MVC Liquid Formulation>=12 - <18 Years of Age, MVC Tablet Formulation
<400 copies/mL; TLOVR Responder62.574.269.248.8
<48 copies/mL; TLOVR Responder43.854.846.244.2
SecondaryPercentage of Participants With >= 1.0 log10 Reduction in HIV-1RNA Concentration From Baseline to Week 24 and Week 48

Percentage of participants with at least a 1.0 log10 reduction in HIV-1 RNA from baseline to Week 24 and Week 48 were tabulated.

Time frame:
Baseline to Week 24, Week 48 post-treatment
Reported as:
Number · percentage of participants
Percentage of Participants With >= 1.0 log10 Reduction in HIV-1RNA Concentration From Baseline to Week 24 and Week 48
percentage of participants>=2 - <6 Years of Age, MVC Liquid Formulation>=6 - <12 Years of Age, MVC Tablet Formulation>=6 - <12 Years of Age, MVC Liquid Formulation>=12 - <18 Years of Age, MVC Tablet Formulation
Baseline to Week 2492.3 (77.8 to 106.8)100.0 (100.0 to 100.0)100.0 (100.0 to 100.0)93.1 (83.9 to 102.3)
Baseline to Week 48100.0 (100.0 to 100.0)96.2 (88.8 to 103.6)100.0 (100.0 to 100.0)88.0 (75.3 to 100.7)
SecondaryChange From Baseline in HIV-1 RNA (Original)

Plasma HIV-1 RNA was determined using the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 Test (lower limit of quantification \[LLOQ\] \<48 copies/mL). Blood samples were taken at the time points indicated in the participant evaluation schedule. Screening HIV-1 RNA \>1000 copies/ml was used to determine eligibility for the study.

Time frame:
Baseline, Week 24, Week 48 post-treatment
Reported as:
Mean · copies/mL
Change From Baseline in HIV-1 RNA (Original)
copies/mL>=2 - <6 Years of Age, MVC Liquid Formulation>=6 - <12 Years of Age, MVC Tablet Formulation>=6 - <12 Years of Age, MVC Liquid Formulation>=12 - <18 Years of Age, MVC Tablet Formulation
Change from Baseline - Original - Week 24-271974.6 ± 391843.59-38764.0 ± 63688.93-58081.0 ± 79720.33-57325.7 ± 172108.62
Change from Baseline - Original - Week 48-267834.2 ± 378896.88-34787.7 ± 60222.60-56351.7 ± 76231.03-55321.1 ± 173840.55
SecondaryChange From Baseline in HIV-1 RNA (Log10 Copies/mL)

Plasma HIV-1 RNA was determined using the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 Test (lower limit of quantification \[LLOQ\] \<48 copies/mL). Blood samples were taken at the time points indicated in the participant evaluation schedule. Screening HIV-1 RNA \>1000 copies/ml was used to determine eligibility for the study.

Time frame:
Baseline, Week 24, Week 48 post-treatment
Reported as:
Mean · Log10 Copies/mL
Change From Baseline in HIV-1 RNA (Log10 Copies/mL)
Log10 Copies/mL>=2 - <6 Years of Age, MVC Liquid Formulation>=6 - <12 Years of Age, MVC Tablet Formulation>=6 - <12 Years of Age, MVC Liquid Formulation>=12 - <18 Years of Age, MVC Tablet Formulation
Change from Baseline - Log10 - Week 24-2.4853 ± 1.1421-2.2324 ± 0.8668-2.1756 ± 1.1854-1.6482 ± 1.3806
Change from Baseline - Log10 - Week 48-2.5831 ± 1.2148-1.9579 ± 1.0861-2.0549 ± 1.2125-1.4591 ± 1.4477
SecondaryChange From Baseline in Cluster of Differentiation 4 (CD4+) Cell Count at Weeks 24 and 48

Change from baseline in CD4 cell count to Week 24 and Week 48 were tabulated in aggregated and broken down by age cohort using summary statistics.

Time frame:
Baseline, Week 24, Week 48 post-treatment
Reported as:
Mean · cells/mm^3
Change From Baseline in Cluster of Differentiation 4 (CD4+) Cell Count at Weeks 24 and 48
cells/mm^3>=2 - <6 Years of Age, MVC Liquid Formulation>=6 - <12 Years of Age, MVC Tablet Formulation>=6 - <12 Years of Age, MVC Liquid Formulation>=12 - <18 Years of Age, MVC Tablet Formulation
Week 24232.7 ± 381.6355.8 ± 294.0213.9 ± 166.4173.6 ± 203.6
Week 48275.9 ± 363.4362.7 ± 373.5167.3 ± 150.9168.6 ± 211.0
SecondaryChange From Baseline in Percentage (%) of CD4+ Cells at Weeks 24 and 48

Change from baseline in CD4 % to Week 24 and Week 48 were tabulated in aggregated and broken down by age cohort using summary statistics.

Time frame:
Baseline, Week 24 and Week 48 post-treatment
Reported as:
Mean · percentage of CD4+ cells
Change From Baseline in Percentage (%) of CD4+ Cells at Weeks 24 and 48
percentage of CD4+ cells>=2 - <6 Years of Age, MVC Liquid Formulation>=6 - <12 Years of Age, MVC Tablet Formulation>=6 - <12 Years of Age, MVC Liquid Formulation>=12 - <18 Years of Age, MVC Tablet Formulation
Week 247.3 ± 5.03.8 ± 7.43.5 ± 4.03.8 ± 6.1
Week 487.5 ± 7.66.0 ± 6.82.5 ± 4.24.6 ± 6.5
SecondaryNumber of Participants With Protocol Defined Virologic Failure

The occurrence of any one of the following criteria would constitute Virologic failure: Criteria A=Decrease from Baseline plasma HIV-1 RNA \<1 log10 and plasma HIV-1 RNA \>400 copies/mL starting at Week 12 and confirmed at consecutive Week 16; Criteria B=Decrease from Baseline plasma HIV-1 RNA \<2.0 log10 and plasma HIV-1 RNA \>400 copies/mL at Week 24 OR plasma HIV-1 RNA \>10,000 copies/mL on and after Week 24, and confirmed within 14 to 21 days; Criteria C=Increase from nadir plasma HIV-1 RNA of \>=1 log10 (\>=1,000 copies/mL if nadir plasma HIV-1 RNA \<48 copies/mL) at any time, and confirmed within 14 to 21 days.

Time frame:
Week 48
Reported as:
Number · participants
Number of Participants With Protocol Defined Virologic Failure
participants>=2 - <6 Years of Age, MVC Liquid Formulation>=6 - <12 Years of Age, MVC Tablet Formulation>=6 - <12 Years of Age, MVC Liquid Formulation>=12 - <18 Years of Age, MVC Tablet Formulation
Criteria A0215
Criteria B0000
Criteria C3328
SecondaryNumber of Participants With Viral Tropism Between Screening and Confirmed Protocol Defined Virologic Failure (PDVF) Prior to Week 48

Virus tropism was determined using the Monogram Biosciences Trofile™ viral tropism assay. Change in detected tropism from screening to the time of failure prior to Week 48 was reported. X4=CXCR4 tropic virus; R5=CCR5-tropic virus; X4=CXCR4-tropic virus. Number of participants as per tropism to respective virus has been reported.

Time frame:
Screening to Week 48
Reported as:
Number · participants
Number of Participants With Viral Tropism Between Screening and Confirmed Protocol Defined Virologic Failure (PDVF) Prior to Week 48
participants>=2 - <6 Years of Age, MVC Liquid Formulation>=6 - <12 Years of Age, MVC Tablet Formulation>=6 - <12 Years of Age, MVC Liquid Formulation>=12 - <18 Years of Age, MVC Tablet Formulation
With valid on-treatment results24311
Tropism at Confirmed PDVF R52329
Tropism at Confirmed PDVF DM0112
Tropism at Confirmed PDVF X40000
Tropism at Confirmed PDVF Not Reportable1001
SecondaryNumber of Participants With Emergence of Reverse Transcriptase Inhibitor (RTI) and Protease Inhibitor (PI) Resistance Associated Mutations (RAMs) Between Screening and On-Treatment Confirmed PDVF

Phenotypic and genotypic susceptibility to reverse transcriptase and protease inhibitors was evaluated at screening using the Monogram Biosciences PhenoSense™ GT (PSGT) assay. Samples from a confirmatory PDVF visit or early termination of MVC were planned to be analyzed if the plasma HIV-1 RNA was ≥400 copies/mL. Data for participants with respective gene mutation category has been reported. Participants with more than one mutation are counted more than once.

Time frame:
48 weeks
Reported as:
Number · participants
Number of Participants With Emergence of Reverse Transcriptase Inhibitor (RTI) and Protease Inhibitor (PI) Resistance Associated Mutations (RAMs) Between Screening and On-Treatment Confirmed PDVF
participants>=2 - <6 Years of Age, MVC Liquid Formulation>=6 - <12 Years of Age, MVC Tablet Formulation>=6 - <12 Years of Age, MVC Liquid Formulation>=12 - <18 Years of Age, MVC Tablet Formulation
With valid on-treatment results24311
PI Minor L10L/F0001
PI Minor L89L/I/M0001
PI Minor V77V/I0001
NNRTI K103K/N0100
NNRTI K103N0011
NRTI M184V0010
PI Minor K20K/R0020
Total with emergence0134
SecondaryPercentage of Participants With Optimized Background Treatment Susceptibility Scores

Data was summarized by the total ARV activity of the background regimen using simple and weighted total optimized background treatment susceptibility scores as well as by screening genotype. Simple total optimized background treatment (OBT) susceptibility scores were categorized as 0, 1, \>=2 and weighted total OBT susceptibility scores were categorized as 0 to 0.5, 1 to 1.5 and \>=2. However, net susceptibility scores were imputed for simple analysis based on genotype. Susceptibility scores indicate the level resistance to the study medication. Scores ranged from 0 to 1 as 1 = susceptible and potential low-level resistance; 0.5 = low and intermediate-level resistance; 0 = high-level resistance, where higher scores indicated lower resistance.

Time frame:
48 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants With Optimized Background Treatment Susceptibility Scores
Percentage of participantsResponsePDVFOther Failure/Remainder
Simple score 0000
Simple score 1.08.24.30
Simple score >=2.081.695.796.8
Weighted score 0-0.56.130.429.0
Weighted score 1.0-1.553.165.229.0
Weighted score >=2.028.64.338.7

Adverse events

Collected over Baseline up to 5 years. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
>=2 - <6 Years of Age, MVC Liquid Formulation0/16 (0%)5/16 (31.3%)12/16 (75%)
>=6 - <12 Years of Age, MVC Tablet Formulation0/31 (0%)5/31 (16.1%)25/31 (80.6%)
>=6 - <12 Years of Age, MVC Liquid Formulation0/13 (0%)3/13 (23.1%)10/13 (76.9%)
>=12 - <18 Years of Age, MVC Tablet Formulation1/43 (2.3%)10/43 (23.3%)34/43 (79.1%)
Most frequent serious events
Showing 10 of 25
Most frequent serious events
Event>=2 - <6 Years of Age, MVC Liquid Formulation>=6 - <12 Years of Age, MVC Tablet Formulation>=6 - <12 Years of Age, MVC Liquid Formulation>=12 - <18 Years of Age, MVC Tablet Formulation
Gastric fistulaGastrointestinal disorders0/160/311/130/43
PneumoniaInfections and infestations0/161/311/132/43
OsteopeniaMusculoskeletal and connective tissue disorders0/160/311/130/43
Pain in extremityMusculoskeletal and connective tissue disorders0/160/311/130/43
PrurigoSkin and subcutaneous tissue disorders0/160/311/130/43
VomitingGastrointestinal disorders1/160/310/130/43
Abscess oralInfections and infestations1/160/310/130/43
Tooth abscessInfections and infestations1/160/310/130/43
OtorrhoeaEar and labyrinth disorders1/160/310/130/43
ConstipationGastrointestinal disorders1/160/310/130/43
Most frequent other events
Showing 10 of 204
Most frequent other events
Event>=2 - <6 Years of Age, MVC Liquid Formulation>=6 - <12 Years of Age, MVC Tablet Formulation>=6 - <12 Years of Age, MVC Liquid Formulation>=12 - <18 Years of Age, MVC Tablet Formulation
DiarrhoeaGastrointestinal disorders7/163/314/139/43
Upper respiratory tract infectionInfections and infestations7/166/312/135/43
VomitingGastrointestinal disorders6/168/313/134/43
Otitis mediaInfections and infestations6/161/311/130/43
NasopharyngitisInfections and infestations4/164/310/133/43
InfluenzaInfections and infestations2/166/313/135/43
Viral upper respiratory tract infectionInfections and infestations3/162/313/131/43
CoughRespiratory, thoracic and mediastinal disorders1/166/312/133/43
BronchitisInfections and infestations3/163/310/137/43
GastroenteritisInfections and infestations3/160/312/132/43

Baseline characteristics

The Full Analysis Set (FAS) consisted of all participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(Years)>=2 - <6 Years of Age, MVC Liquid Formulation>=6 - <12 Years of Age, MVC Tablet Formulation>=6 - <12 Years of Age, MVC Liquid Formulation>=12 - <18 Years of Age, MVC Tablet FormulationTotal
Mean3.4 ± 0.99.1 ± 1.78.9 ± 2.014.0 ± 1.610.3 ± 4.1
Sex: Female, Male
Sex: Female, Male(Participants)>=2 - <6 Years of Age, MVC Liquid Formulation>=6 - <12 Years of Age, MVC Tablet Formulation>=6 - <12 Years of Age, MVC Liquid Formulation>=12 - <18 Years of Age, MVC Tablet FormulationTotal
Female51662754
Male111571649
08

Study locations

41 sites
  • Children's Hospital Los Angeles
    Los Angeles, California 90027, United States
  • Children's Hospital of Orange County
    Orange, California 92868, United States
  • Alfred I. DuPont Hospital for Children
    Wilmington, Delaware 19803, United States
  • Children's National Medical Center
    Washington, District of Columbia 20010, United States
  • Rainbow Center at University of Florida Health
    Jacksonville, Florida 32209, United States
  • University of Miami Miller School of Medicine
    Miami, Florida 33136, United States
  • University of South Florida
    Tampa, Florida 33612, United States
  • Grady Health System, IDP
    Atlanta, Georgia 30308, United States
  • Children's Healthcare of Atlanta
    Atlanta, Georgia 30322, United States
  • Pediatric Infectious Disease Clinic
    Jackson, Mississippi 39213, United States
  • Batson Specialty Clinic
    Jackson, Mississippi 39216, United States
  • University of Mississippi
    Jackson, Mississippi 39216, United States
  • Cincinnati Center for Clinical Research
    Cincinnati, Ohio 45206, United States
  • Children's Medical Center of Dallas
    Dallas, Texas 75235, United States
  • Children's Memorial Hermann Hospital
    Houston, Texas 77030, United States
  • UT Physician
    Houston, Texas 77030, United States
  • VCU Health System Clinical Research Services
    Richmond, Virginia 23298, United States
  • Virginia Commonwealth University
    Richmond, Virginia 23298, United States
  • Instituto de Infectologia Emilio Ribas
    São Paulo, SP 01246-900, Brazil
  • Condomínio Edifício Parque Paulista
    São Paulo, 01416-000, Brazil
  • Clinica Pediatrica Azienda Ospedaliera di Padova
    Padova, 35128, Italy
  • Farmacia Interna
    Padova, 35128, Italy
  • IRCCS Ospedale Pediatrico Bambino Gesu
    Roma, 00165, Italy
  • Struttura Complessa a Direzione Universitaria Immunologia, Reumatologia e Malattie Infettive
    Torino, 10126, Italy
  • Hospital Infantil de Mexico Federico Gomez
    Mexico, DF 06720, Mexico
  • Centro Hospitalar Universitario do Algarve, EPE
    Faro, 8000-386, Portugal
  • Centro Hospitalar de Lisboa Central, EPE
    Lisboa, 1169-045, Portugal
  • Centro Hospitalar de Lisboa Norte, EPE
    Lisboa, 1649-035, Portugal
  • Hospital S. João, E.P.E
    Porto, 4202-451, Portugal
  • Hospital San Juan Research Unit
    San Juan, 00935, Puerto Rico
  • Iatros International
    Bloemfontein, FREE State 9301, South Africa
  • Lakeview Hospital
    Benoni, Gauteng 1501, South Africa
  • Dr George Mukhari Hospital
    Ga-Rankuwa, Gauteng 0208, South Africa
  • Dr. Jan Fourie Medical Centre
    Dundee, Kwazulu-natal 3000, South Africa
  • Embassy Drive Medical Center
    Pretoria, 0083, South Africa
  • Hospital Sant Joan de Deu
    Esplugues De Llobregat, Barcelona, 08950, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
  • Department of Pediatrics, Faculty of Medicine, Chiang Mai University
    Muang, Chiang MAI 50200, Thailand
  • Department of Pediatric, Faculty of Medicine, Khon Kaen University
    Muang, Khon Kaen 40002, Thailand
  • The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT),
    Bangkok, 10330, Thailand
  • Department of Pediatrics, Faculty of Medicine, Siriraj Hospital
    Bangkok, 10700, Thailand
09

References and documents

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2009 to primary completion in Apr 2015, 71 months.

Results were first posted in Feb 2016, 10 months after primary completion.

Of 29 industry-sponsored phase 2 interventional studies under Acquired Immunodeficiency Syndrome, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 71. This study's 71 months is above that.

Counting every sponsor, half of 86 studies reached it within 36 months; a quarter within 18 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2008
First posted
Nov 14, 2008
StartActual
Apr 22, 2009
Primary completionActual
Apr 14, 2015
CompletionEst.
Jun 30, 2023
Results first posted
Feb 25, 2016
Last update
Apr 28, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 28, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00791700
Lead sponsor
ViiV Healthcare
Collaborators
Pfizer
Responsible party
Sponsor
First posted
Nov 14, 2008
Start date
Apr 22, 2009
Primary completion
Apr 14, 2015
Completion
Jun 30, 2023 (estimated)
Results posted
Feb 25, 2016
Last update
Apr 28, 2020

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Maraviroc

Start the discussion